Page 80 - Read Online

Liu EH, Metz DC, Phan AT,Sippel RS, Strosberg JR, Yao JC; North follow-up. Ann Oncol 2012;23:120-3.
American Neuroendocrine Tumor Society. Consensus guidelines 43. Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim
for the management and treatment of neuroendocrine tumors. E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS
Pancreas 2013;42:557-77. consensus conference participants. Pulmonary neuroendocrine
30. Jilesen AP, Busch OR, van Gulik TM, Gouma DJ, Nieveen (carcinoid) tumors: European Neuroendocrine Tumor Society
van Dijkum EJ. Standard pre- and postoperative determination expert consensus and recommendations for best practice for typical
of chromogranin a in resectable non-functioning pancreatic and atypical pulmonary carcinoids. Ann Oncol 2015;26:1604-20.
neuroendocrine tumors--diagnostic accuracy: NF-pNET and low 44. Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge
tumor burden. Dig Surg 2014;31:407-14. U, Öberg K, Pavel M, Perren A, Toumpanakis C, O’Connor J,
31. O’Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova O’Toole D, Krenning E, Reed N, Kianmanesh R; all other Vienna
J, O’Connor J, Pape UF, Plöckingerg U and all other Mallorca Consensus Conference participants. ENETS Consensus Guidelines
Consensus Conference participants. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasm of the Jejunum and Ileum.
for the Standards of Care in Neuroendocrine Tumors: Biochemical Neuroendocrinology 2016;103:125-38.
Markers. Neuroendocrinology 2009;90:194-202. 45. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem
32. Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson
Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, B, Siegler M, Caplin M, Solcia E, Schilsky R; Working Group
Goldner WS, Halfdanarson TR, Heslin MJ, Kan-deel F, Kunz PL, on Neuroendocrine Liver Metastases. Recommendations for
Kuvshinoff BW 2nd, Lieu C, Moley JF, Munene G, Pillarisetty management of patients with neuroendocrine liver metastases.
VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao Lancet Oncol 2014;15:8-21.
JC, Burns J, Freedman-Cass D; National comprehensive cancer 46. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum
network. Neuroendocrine tumors, version 1.2015. J Natl Compr gastrin in Zollinger-Ellison syndrome: I. Prospective study of
Canc Netw 2015;13:78-108. fasting serum gastrin in 309 patients from the National Institutes
33. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, of Health and comparison with 2229 cases from the literature.
Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell- Medicine (Baltimore) 2006;85:295-330.
Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, 47. Massironi S, Conte D, Sciola V, Spampatti MP, Ciafardini C, Valenti
Toubanakis C, Valle J, Verbeke C, Grossman AB. Guidelines for the L, Rossi RE, Peracchi M. Plasma chromogranin A response to
management of gastroenteropancreatic neuroendocrine (including octreotide test: prognostic value for clinical outcome in endocrine
carcinoid) tumours (NETs). Gut 2012;61:6-32. digestive tumors. Am J Gastroenterol 2010;105:2072-8.
34. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St. Peter J, Cherfi 48. Massironi S, Rossi RE, Casazza G, Conte D, Ciafardini C, Galeazzi
A, Öberg KE. Chromogranin A and neuron-specific enolase as M, Peracchi M. Chromogranin A in diagnosing and monitoring
prognostic markers in patients with advanced pNET treated with patients with gastroenteropancreatic neuroendocrine neoplasms:
everolimus. J Clin Endocrinol Metab 2011;96:3741-9. a large series from a single institution. Neuroendocrinology
35. van Adrichem RC, Kamp K, Vandamme T, Peeters M, Feelders RA, 2014;100:240-9.
de Herder WW. Serum neuron-specific enolase level is an independent 49. Rossi RE, Garcia-Hernandez J, Meyer T, Thirlwell C, Watkins J,
predictor of overall survival in patients with gastroenteropancreatic Guy Martin N, Caplin ME, Toumpanakis C. Chromogranin A as
neuroendocrine tumors. Ann Oncol 2015; 27:746-7. a predictor of radiological disease progression in neuroendocrine
36. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis tumours. Ann Transl Med 2015;3:118.
LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, 50. Jensen EH, Kvols L, McLoughlin JM, Lewis JM, Alvarado MD,
Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future Yeatman T, Malafa M, Shibata D. Biomarkers predict outcomes
directions in the treatment of neuroendocrine tumors: consensus following cytoreductive surgery for hepatic metastases from
report of the National Cancer Institute Neuroendocrine Tumor functional carcinoid tumors. Ann Surg Oncol 2007;14:780-5.
Clinical Trials Planning Meeting. J Clin Oncol 2011;29:934-43. 51. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder
37. Vinik AI, Woltering EA, Warner RP, Caplin M, O’Dorisio TM, WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP.
Wiseman GA, Coppola D, Go WLW. NANETS consensus Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate
guidelines for the diagnosis of neuroendocrine tumor. Pancreas in patients with endocrine gastroenteropancreatic tumors. J Clin
2010;39:713-34. Oncol 2005;23:2754-62.
38. Phan AT, Oberg K, Choi J, Harrison LH Jr, Hassan MM, 52. Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson
Strosberg JR, Krenning EP, Ko-cha W, Woltering EA, Maples WJ. O, Jansson S, Wängberg B, Ahl-man H. Orthotopic liver
NANETS consensus guideline for the diagnosis and management or multivisceraltransplantation as treatment of metastatic
of neuroendocrine tumors: well-differentiated neuroendocrine neuroendocrine tumors. Liver Transpl 2007;13:327-33.
tumors of the thorax (includes lung and thymus). Pancreas 53. Modlin IM, Drozdov I, Alaimo D, Callahan S, Teixiera N, Bodei
2010;39:784-98. L, Kidd M. A multianalyte PCR blood test outperforms single
39. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, analyte ELISAs (chromogranin A, pancreastatin, neurokinin
Goldsmith SJ, Nutting CDO, Bushnell DL, Caplin ME, Yao JC. The A) for neuroendocrine tumor detection. Endocr Relat Cancer
NANETS Consensus Guideline for the diagnosis and management 2014;21:615-28.
of neuroendocrine tumors: well-differentiated neuroendocrine 54. Modlin IM, Aslanian H, Bodei L, Drozdov I, Kidd M. A PCR
tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas blood test outperforms chromogranin A in carcinoid detection
2010;39:753-66. and is unaffected by proton pump inhibitors. Endocr Connect
40. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith 2014;3:215-23.
SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, 55. Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley
Jensen RT. NANETS treatment guidelines: well-differentiated JA, Caplin ME, Meyer T. Circulating tumor cells as prognostic
neuroendocrine tumors of the stomach and pancreas. Pancreas markers in neuroendocrine tumors. J Clin Oncol 2013;31:365-72.
2010;39:735-52. 56. Khan MS, Kirkwood AA, Tsigani T, Lowe H, Goldstein R,
41. Öberg K, Knigge U, Kwekkeboom D, Perren A on behalf of the Hartley JA, Caplin ME, Meyer T. Early changes in circulating
ESMO Guidelines Working Group. Neuroendocrine gastro- tumor cells are associated with response and survival following
entero-pancreatic tumors: ESMO Clinical Practice Guidelines for treatment of metastatic neuroendocrine neoplasms. Clin Cancer
diagnosis, treatment and follow-up. Annals Oncol 2012;23:124-30. Res 2016;22:79-85.
42. Öberg K, Hellman P, Ferolla P, Papotti M; ESMO Guidelines 57. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E.
Working Group. Neuroendocrine bronchial and thymic tumors: Priorities for improving the management of gastroenteropancreatic
ESMO Clinical Practice Guidelines for diagnosis, treatment and neuroendocrine tumors. J Natl Cancer Inst 2008;100:1282-9.

356
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 31, 2016 ¦